| |
|
|
|
|
| Slide Lecture Programs |
| 2004 Core Curriculum |
Impact of vascular biology on cardiovascular disease, risk prevention, and treatment
Section I: Atrial fibrillation, anticoagulation, and stroke prevention |
April 16, 2004
|
| E: |
Emerging new options
Profile of direct thrombin inhibition
- In summary, SPORTIF III and V demonstrated that oral ximelagatran was at least as effective as dose-adjusted warfarin in prevention of stroke in AF patients at high risk for this outcome.1,2
- Further, ximelagatran caused less bleeding than warfarin and offered fixed oral dosing without the need for coagulation monitoring.
1Executive Steering Committee on behalf of the SPORTIF Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet. 2003;362:1691-1698.
2Halperin JL. Stroke prevention using the direct oral thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation: SPORTIF V. Presented at: AHA Scientific Sessions 2003; Nov 11, 2003; Orlando, Fla.
|
|
|
Resources